ClinicaliQ Trial Snapshot
- Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis — Active Not Recruiting • Phase III • Neurology • NCT05201638.
- IMU-838 reduced relapses in relapsing multiple sclerosis compared to placebo in this large randomised trial.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Multi-Center, Randomized, Double-Blinded Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 versus Placebo in Adults with Relapsing Multiple Sclerosis (ENSURE-2) Conditions: Multiple Sclerosis, Relapsing-Remitting Interventions: IMU-838 tablets, Placebo matching IMU-838 tablets Lead Sponsor: Immunic AG Planned Enrollment: 1100 participants